Pain Therapeutics Market, market research

Report Overview

One in five people suffer from moderate to severe chronic pain, and one in three is unable or less able to maintain an independent lifestyle due to their pain. Between 50 and 60% of people with chronic pain are less able or unable to exercise, sleep normally, perform household chores, attend social activities, drive a car, or walk.

The value of the pharmaceutical market for pain relief in 2007 reflects this seeming worldwide epidemic of pain. The Global Pain Therapeutics Market assesses key pain management therapeutics such as opioids, triptans, anticonvulsants, Cox-II inhibitors and traditional NSAIDs and are discussed in terms of their past, present and future value and the role they are playing in the effective management of pain.

This report discusses the key products within each of these areas and outlines the drivers of these markets as well as the restraints on them. The Global Pain Therapeutics Market also identifies and discusses trends and issues that will have a significant impact on the pain management market and profiles the leading companies in the field. The report provides the reader with valuable information and analysis regarding key products on the market and in clinical development.

This 408-page report includes 96 profiles of companies engaged in the development and/or commercialization of pain therapeutics and over 160 tables and graphs illustrating sales trends, past and present, as well as pipelines and demographic and market trends in the area of pain management.

Key features and highlights of this report:

Extensive review of key products indicated for pain conditions and their market value and impact
Discussion of the key drivers of and restraints on the global pain therapeutics market
Qualitative analysis of key pain markets and products driving growth (opioids, NSAIDs, triptans, neuropathic pain therapies (anticonvulsants) and Cox-II inhibitors)
Profiles and reviews of key pipeline products in development for fibromyalgia, cancer pain, post-operative pain, migraine pain, neuropathic pain and opioid therapies
Profiles of nearly 100 companies engaged in the development and/or commercialization of pain therapeutics worldwide
Overviews of treatment options for post-operative pain, migraine pain, cancer pain, fibromyalgia, arthritic pain, back pain, neuropathic pain, and the demographic impact of these conditions.
Chapter devoted to the role of drug delivery technologies in the current and future treatment of pain
Discussion of promising areas of research in a variety of pain areas and companies engaged in cutting edge research and development

Key questions answered in this report:

What is the current state of the global pain therapeutics market?
How has the Cox-II debacle effected the market for and treatment of pain conditions?
What pain therapies, old and new, are today proving their market and clinical value?
What new classes of pain therapeutics are in clinical development and which classes and therapies are demonstrating superior efficacy?
Which diseases and conditions have the most room for growth in terms of unmet need and market demand?

Report Audience

Clients include leading multinationals, specialty pharmaceutical companies, investment and consulting firms, and many others. Some of our clients include:

Allergan.....Bayer...........Catalyst Pharma...........Ferndale Labs

Ipsen........Acrux .. Pfizer.. ..Boston Consulting........ Cephalon.

Nycomed...........Solvay..........Organon. . ..Roche..... Schering

Galderm.......Boehringer ........Merck... .....BioTie Therapeutics

Cephalon...........Stiefel Labs.....Morgan Stanley.. ..MacSmith..